Klein Matthew B. 4

What Happened Matthew B. Klein, CEO of PTC Therapeutics (PTCT), sold 7,371 shares on Feb 18, 2026 at $69.36 per share, generating roughly $511,253 in proceeds. The sale was an automatic sell-to-cover to satisfy tax withholding obligations related to the vesting of 17,500 RSUs from a February 15, 2025 grant.

Key Details

• Transaction date & price: 2026-02-18, 7,371 shares at $69.36 each.
• Total proceeds: Approximately $511,253.
• Shares owned after transaction: Not specified in the Form 4 filing.
• Footnote: F1 indicates the shares sold were automatically sold pursuant to an irrevocable sell-to-cover election to satisfy taxes on 17,500 vested RSUs (from a 70,000 RSU grant dated 2/15/2025).
• Transaction code: S (Sale); executed as a sell-to-cover (open-market sale to cover tax withholding).
• Filing timeliness: Marked "L" (late). The Form 4 was filed on 2026-02-20 for a 2026-02-18 transaction, reducing the promptness of public disclosure.

Context A sell-to-cover is a routine administrative sale where some vested RSU shares are sold to pay withholding taxes; here, about 7,371 of the 17,500 vested RSUs were sold, implying roughly 10,129 vested shares remained (per the footnote math). Such transactions are common after RSU vesting and do not necessarily reflect the insider's broader view of the company.